These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 17919701)
21. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706 [TBL] [Abstract][Full Text] [Related]
22. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Roh MH; Kindelberger D; Crum CP Am J Surg Pathol; 2009 Mar; 33(3):376-83. PubMed ID: 19011565 [TBL] [Abstract][Full Text] [Related]
23. Value of elastin staining in the assessment of peritoneal implants associated with ovarian serous borderline tumours. Stewart CJ; Brennan BA; Crook ML; Russell P Histopathology; 2007 Sep; 51(3):313-21. PubMed ID: 17727474 [TBL] [Abstract][Full Text] [Related]
24. [Expression of AIB1 protein in epithelial ovarian cancer cells and its impact on apoptosis]. Han XY; Chen Y; Hou MM; Zhang J; Yang KX; Chen YY; Qie MR Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 39(4):619-22, 634. PubMed ID: 18798508 [TBL] [Abstract][Full Text] [Related]
25. Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study. Jewell EL; Darcy KM; Hutson A; Lee PS; Havrilesky LJ; Grace LA; Berchuck A; Secord AA Gynecol Oncol; 2009 Dec; 115(3):424-9. PubMed ID: 19767063 [TBL] [Abstract][Full Text] [Related]
26. Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Köbel M; Huntsman D; Gilks CB Expert Rev Mol Med; 2008 Aug; 10():e22. PubMed ID: 18671886 [TBL] [Abstract][Full Text] [Related]
27. Immunoexpression of beta-catenin--E-cadherin complex in primary serous ovarian tumors. Stawerski P; Wagrowska-Danilewicz M; Stasikowska O; Gottwald L; Danilewicz M Pol J Pathol; 2008; 59(1):27-32. PubMed ID: 18655368 [TBL] [Abstract][Full Text] [Related]
28. Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study. Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S J Med Assoc Thai; 2009 Mar; 92(3):308-14. PubMed ID: 19301721 [TBL] [Abstract][Full Text] [Related]
29. Normalization of the ovarian cancer microenvironment by SPARC. Said N; Socha MJ; Olearczyk JJ; Elmarakby AA; Imig JD; Motamed K Mol Cancer Res; 2007 Oct; 5(10):1015-30. PubMed ID: 17951402 [TBL] [Abstract][Full Text] [Related]
30. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression. Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951 [TBL] [Abstract][Full Text] [Related]
31. Re-assessment of the high-grade serous ovarian cancer phosphoproteome - Identification of kinase candidates in TCGA tumors for future clinical intervention. Rolfs F; Piersma SR; Jimenez CR EBioMedicine; 2019 Mar; 41():34-35. PubMed ID: 30797713 [No Abstract] [Full Text] [Related]
32. E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomas. De Meyer T; Bijsmans IT; Van de Vijver KK; Bekaert S; Oosting J; Van Criekinge W; van Engeland M; Sieben NL J Pathol; 2009 Jan; 217(1):14-20. PubMed ID: 18991331 [TBL] [Abstract][Full Text] [Related]
33. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282 [TBL] [Abstract][Full Text] [Related]
34. [Clinical aspects in expression of epidermal growth factor receptors in epithelial ovarian tumors]. Tomov S; Gorchev G; Khinkova N; Tsingilev D Akush Ginekol (Sofiia); 2007; 46(4):29-33. PubMed ID: 17974192 [No Abstract] [Full Text] [Related]
35. The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor. Tsuchiya T; Nakahama K; Asakawa Y; Maemura T; Tanaka M; Takeda S; Morita M; Morita I Gynecol Endocrinol; 2009 Feb; 25(2):104-9. PubMed ID: 19253105 [TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor D and intratumoral lymphatics as independent prognostic factors in epithelial ovarian carcinoma. Li L; Liu B; Li X; Yang S; Xiao J; Chen M; Zhang Y; Ma J Anat Rec (Hoboken); 2009 Apr; 292(4):562-9. PubMed ID: 19226617 [TBL] [Abstract][Full Text] [Related]
38. Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center. Storey DJ; Rush R; Stewart M; Rye T; Al-Nafussi A; Williams AR; Smyth JF; Gabra H Cancer; 2008 May; 112(10):2211-20. PubMed ID: 18344211 [TBL] [Abstract][Full Text] [Related]
39. Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma. Li XQ; Zhang SL; Cai Z; Zhou Y; Ye TM; Chiu JF Cancer Lett; 2009 Mar; 275(1):109-16. PubMed ID: 19056166 [TBL] [Abstract][Full Text] [Related]
40. Long-term semi-permanent catheter use for the palliation of malignant ascites. Brooks RA; Herzog TJ Gynecol Oncol; 2006 May; 101(2):360-2. PubMed ID: 16499957 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]